NCT07436312 Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
| NCT ID | NCT07436312 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2026-05-04 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 170 participants in total. It began in 2026-05-04 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The U-TRANS study was initiated by Gustave Roussy, which is its sponsor\*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet among people at high risk of cancer (WCRF score ≤ 5, corresponding to low adherence to nutritional cancer prevention recommendations: eating a diet rich in whole grains, vegetables, fruit and fibre, and limiting ultra-processed foods, red meat, processed meats, sugary drinks and alcohol). It assesses the impact of a digital intervention (based on the use of the Open Food Facts app) as a complement to the nutritional education provided by the Interception program.
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years, 2. Individuals at increased risk of different cancers as defined within the Interception program, 3. With a baseline WCRF score ≤ 5 at entry in the Interception program, 4. Agreeing to participate and who have given their written agreement for the study, 5. Agreeing to fill in the questionnaires on the dedicated platform for the duration of the study, 6. Participant have and accept to use their smartphone, 7. All participants must understand spoken and written French language Exclusion Criteria: 1. Psychiatric disorders or cognitive impairments precluding participation, 2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
Contact & Investigator
Bruno Raynard, MD
STUDY CHAIR
Gustave Roussy, Villejuif, France
Frequently Asked Questions
Who can join the NCT07436312 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436312 currently recruiting?
Yes, NCT07436312 is actively recruiting participants. Contact the research team at bruno.raynard@gustaveroussy.fr for enrollment information.
Where is the NCT07436312 trial being conducted?
This trial is being conducted at Avignon, France, Rennes, France, Villejuif, France.
Who is sponsoring the NCT07436312 clinical trial?
NCT07436312 is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. The principal investigator is Bruno Raynard, MD at Gustave Roussy, Villejuif, France. The trial plans to enroll 170 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.